Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis

Abstract

Background Health systems are struggling with unprecedented drug spending and governments have devised various policy options to manage high-priced medicines. Meanwhile, some pricing and reimbursement processes are currently moving under the jurisdiction of international agreements. This study aims to understand trends in international agreements from the perspectives of pricing and reimbursement policies for newly marketed medicines. Methods We proposed the framework to interpret the international agreements as code and applied computational text analysis to understand international agreements as data. In particular, we selected the AUSFTA, KORUS, and TPP to assess the progress and evolution in international agreements and investigate the existing relevant content on the pricing and reimbursement of newly marketed medicines. Results Similar to the provisions for intellectual property, the scope of international agreements regarding pricing and reimbursement decisions are broadened and strengthened. Over time, the domain of transparency, re-naming procedural fairness, has changed significantly more than the remaining domains. Pharmaceutical companies will have more opportunities to advocate for their positions, to protect their interests in decision processes, to investigate the decisions on listings and setting the amounts of reimbursement, and to challenge these decisions. Conclusions Recently signed international agreements favor companies over governments with underscoring procedural fairness and timely access. However, access to affordable medicines is the goal towards which international agreements should aim. In a similar vein, substantial fairness and the accountability of companies should be discussed when negotiating agreements or adopting international agreements through domestic legislation.

The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration

“…Notwithstanding the increasing requirement for pricing agreements between pharmaceutical companies and health care payers [ 129 , 130 ], for drugs that will be marketed by a company for prescription by physicians, regulatory approval (marketing authorization) can be regarded as the ‘final milestone’. This is not necessarily the case for drugs that will be used by the public health systems of LMICs.…”

Fighting Cancer around the World: A Framework for Action

“…The cost of many cancer drugs makes for an economic challenge for many countries in Africa, compounded by increased uncertainty about new medicines’ cost-effectiveness. Attempts are being made to minimize some of the risks through the use of international trade agreements [ 110 ]. Many of the countries in Africa have fragmented reimbursement systems with multiple actors involved in the purchasing of pharmaceuticals, delivery of health care, and reimbursement mechanisms.…”